High Grade Ovarian Serous Adenocarcinoma Clinical Trial
— DECIDEROfficial title:
Integration of Multiple Data Levels to Improve Diagnosis, Predict Treatment Response and Suggest Targets to Overcome Therapy Resistance in High-grade Serous Ovarian Cancer
Chemotherapy resistance is the greatest contributor to mortality in advanced cancers and severe challenges remain in finding effective treatment modalities to cancer patients with metastasized and relapsed disease. High-grade serous ovarian cancer (HGSOC) is typically diagnosed at a stage where the disease is already widely spread to the abdomen and current standard of practice treatment consists of surgery followed by platinum-taxane based chemotherapy and maintenance therapy. While 90% of HGSOC patients show no clinically detectable signs of cancer after surgery and chemotherapy, only 43% of the patients are alive five years after diagnosis because of chemoresistant cancer. This prospective, observational trial focuses on revealing major mechanisms causing chemoresistance in HGSOG patients and derive personalized treatment regimens for chemotherapy resistant HGSOC patients. The investigators recruit newly diagnosed advanced stage HGSOC patients who are then thoroughly followed during their cancer treatment. Longitudinal sampling includes digitalized H&E stained histology slides mainly collected during routine diagnostics, fresh tumor & ascites samples for next-generation sequencing/proteomics (WGS, RNA-seq, DNA-methylation, ChIP-seq, mass cytometry, etc.) and ex vivo experiments, plasma samples for circulating tumor DNA (ctDNA) analyses. Broad range of clinical parameters such as laboratory and radiologic parameters (e.g., FDG PET/CT), given cancer treatments and their outcomes are collected. The general objective is to establish a clinically useful precision oncology approach based on multi-level data collected in longitudinal setting, and translate the most potent and validated discoveries into clinical use. DECIDER project will produce AI-powered diagnostic tools, cutting-edge software platforms for clinical decision-making, novel data analysis & integration methods, and high-throughput ex vivo drug screening approaches.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | December 2029 |
Est. primary completion date | December 2027 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients with a suspected ovarian cancer diagnosis treated at the Turku University Hospital - Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: - Age <18 years, too poor condition for active treatment (surgery, chemotherapy) - FDG PET/CT scan is not performed for patients with diabetes mellitus and poor glucose balance. |
Country | Name | City | State |
---|---|---|---|
Finland | Turku University Hospital | Turku |
Lead Sponsor | Collaborator |
---|---|
Turku University Hospital | University of Helsinki |
Finland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Successful clinical translation | The magnitude of successful clinical translation is measured by the number of times project-derived personalized medicine has impacted patients care by application of novel and existing biomarkers and therapies. | 5 years | |
Primary | Successful prediction of patient outcome with AI methods | Proportion of patients whose disease outcome (PFS, OS) is predicted correctly with digital histopathology images, genomic data and routine laboratory values | 5 years | |
Secondary | Successful validation of potentially druggable genetic alterations | Number of potentially druggable genetic alterations found and validated with in-vitro methods | 5 years | |
Secondary | Successful prediction of genomic features from tumor histology | Number of genomic features that can be successfully recognized from tumor histology | 5 years | |
Secondary | Prediction of primary treatment response from tumor histology using H&E stained whole slide images and AI-based methods | Number of patients whose outcome (primary therapy outcome, PFS) is predicted correctly | 5 years | |
Secondary | Establishment of an updated version of Chemoresponse score (CRS) for measuring histological effect in tumor tissue after chemotherapy | Predictive power of the updated CRS at interval surgery is compared with traditional CRS | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03924245 -
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
|
Phase 1 | |
Recruiting |
NCT05114421 -
Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
|
Phase 2 | |
Terminated |
NCT03606486 -
Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer
|
N/A | |
Active, not recruiting |
NCT02208375 -
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
|
Phase 1/Phase 2 | |
Recruiting |
NCT06451497 -
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03943173 -
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery
|
Early Phase 1 | |
Completed |
NCT02316834 -
Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
|
Early Phase 1 | |
Recruiting |
NCT05961124 -
Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer
|
Phase 2 | |
Withdrawn |
NCT02756130 -
Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05329532 -
Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03586661 -
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03907852 -
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04794322 -
Developing a Test for the Detection of Ovarian Cancer
|